Arcutis Expands Board of Directors with Appointment of Chris Peetz
View original at finance.yahoo.comO que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis. Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commercial franchises, and successfully growing pipelines through strategic acquisitions. His expertise will strengthen our Board as we continue to execute our strategy to grow the ZORYVE (roflumilast) franchise, expand ZORYVE into new indications, and build our pipeline including evaluating external innovation.
60% confidenceI am honored to join the Arcutis Board of Directors at such an exciting time for the company. Arcutis has built a strong foundation driven by a clear vision and a deep commitment to improving the lives of people living with immune-mediated skin diseases. I look forward to partnering with the Board and leadership team to support the company's continued growth and success.
60% confidenceOn behalf of the Board of Directors, I am pleased to welcome Chris to Arcutis. Throughout his career, Chris has demonstrated an exceptional ability to build and scale innovative biopharmaceutical organizations, guiding the successful development and commercialization of multiple products across a range of indications. His strategic insight, operational experience, and proven leadership will be invaluable to our Board as Arcutis continues its next phase of growth.
60% confidence